Defined beyond CRISPR-Cas9, base editing delivers single nucleotide precision and early promise in treating genetic disease.
Introduction
CRISPR-Cas9 introduced precise genome editing, but its reliance on double-strand DNA breaks raises risks of off-target mutations and unwanted repair. Base editing refines this process by enabling single base substitutions without cutting both strands, offering a safer, more predictable approach.
How does Base Editing work?
Base editors couple a catalytically impaired Cas protein to a DNA-modifying enzyme, such as cytidine or adenine deaminase. This allows targeted conversion of C→T or A→G bases, correcting pathogenic point mutations at single-nucleotide resolution.
Breakthroughs in Base Editing: Clinical trials
The first in vivo use of base editing in humans was reported for transthyretin amyloidosis (NTLA-2001, NEJM 2022).
A single infusion was found to produce:
- >80% reduction in circulating TTR protein, sustained at follow-up.
- No serious safety events attributable to editing.
- Demonstration that base editing can be delivered systemically using lipid nanoparticles.
Considerations in regards to Base Editing
Base editing offers improved precision over CRISPR-Cas9, avoids double strand breaks, and holds potential to treat thousands of monogenic diseases caused by point mutations. However, there are limitations, these include, restriction to specific types of base changes, delivery challenges, and the need for long term monitoring to ensure absence of rare off target effects.
Base editing represents the evolution of genome engineering, combining precision, safety, and therapeutic potential. Its early success in transthyretin amyloidosis suggests broad applicability, but clinical translation will require addressing delivery barriers, regulatory oversight, and equitable access.
Conclusion
As the first patients treated with base editing show durable clinical benefit, the technology is projected to expand the scope of genetic medicine. With refinement, base editing may one day allow correction of pathogenic mutations at scale, transforming treatment of inherited disease from management to cure.